BACKGROUND: Continuous-flow left ventricular assist devices (LVADs) such as the
HeartMate II have become the therapy of choice in patients with end-stage heart failure. The …

The use of continuous-flow left ventricular assist devices (CF-LVADs) has revolutionized the
landscape of mechanical circulatory support for patients with heart failure. Clinical trials are …

BACKGROUND: Pulsatile left ventricular assist devices (LVADs) are effective as bridge-to-
transplant therapy, but they are limited by their large size and lack of durability. Smaller …

Objectives: The aim of this study was to determine whether results with the HeartMate (HM) II
left ventricular assist device (LVAD)(Thoratec Corporation, Pleasanton, California) in a …

Left ventricular assist devices (LVADs) have emerged as a beneficial therapeutic strategy
proven to improve the morbidity and mortality of patients with advanced heart failure …

OBJECTIVES We evaluated our single-centre clinical experience with the HeartMate II (HM
II) left ventricular assist device (LVAD) as a bridge to transplantation (BTT) in end-stage …

Background Continuous-flow left ventricular assist devices (LVADs) have become the
standard of care for patients with advanced heart failure. The goal of this study was to review …

Heart failure continues to be a growing health problem, eluding large-scale improvement
and treatment. Cardiac transplantation has been the gold standard treatment with high post …

Objectives The excellent results with left ventricular assist devices (LVADs) have
revolutionized the treatment options for end-stage heart failure. The use of pulsatile devices …

BACKGROUND: Although continuous-flow left ventricular assist devices (LVAD) are durable
and reliable, device replacement will be inevitable in some patients. We evaluated the …